



This work has been supported by Croatian Science Foundation under the project UIP-2013-11-1533 "Molecular mechanisms of PVR (CD155) immunological pathways in viral and tumor pathogenesis" (PVRreg)

WORKSHOP ON TRANSLATION OF RESEARCH RESULTS INTO BUSINESS OPPORTUNITIES: COMMERCIALISATION OF MONOCLONAL ANTIBODIES WITH ANTI-PVR ANTIBODIES IN FOCUS

Thursday, 5th May 2016

Lecture hall

Faculty of Medicine, Brace Branchetta 20, Rijeka

Talks in frame of the Intellectual Property Week

10:30 – 11:00	Welcome reception
11:00 – 11:30	Dr. Shoshi Keynan , Head of Business Development - Healthcare <i>Yissum, technology transfer company of the Hebrew University of Jerusalem, Israel</i> Technology transfer system of the Hebrew University of Jerusalem
11:30 – 12:00	Ms. Vered Hornik , Registered patent attorney <i>Webb & Co. Patent Attorneys, Israel</i> Patenting of monoclonal antibodies: what can be patented and how is it done?
12:00 – 12:30	Dr. Pinchas Tsukerman , postdoctoral researcher <i>Hebrew University of Jerusalem, Israel</i> Anti-tumor activation of immune cells by monoclonal antibodies
12:30 - 13:30	Lunch